Kymera Therapeutics

A New Wave of Transformational Therapies

Our Focused Path from Target ID to Patients

Since our founding in 2016, Kymera has been singularly focused on the development and application of industry-leading tools to identify E3 ligases and ligands and map the complex processes involved in protein degradation. With increasing command of E3 biology, proprietary tools and predictive modeling capabilities, we can enhance the speed, efficiency and scalability of our pipeline to deliver novel protein degrader therapies.

Today, Kymera is swiftly mobilizing by leveraging our knowledge and pre-clinical data packages to rapidly advance multiple drug candidate programs in oncology and immunology, with an eye on other therapeutics areas as well. We are pursuing a number of targets and pathways that have been largely undruggable. These are first-in-class protein degrader therapies with the potential to deliver truly breakthrough therapies for patients with limited to no known treatment options.

Pathway Program Indication(s) Discovery Pre-Clinical Clinical Next
Milestone
Rights*

IL–1R/
TLR
IRAK4 HS (Focus), AD, RA, Others KT-474
Next Generation
IRAKIMiD
(IRAK4, Ikaros, Aiolos)
MYD88
MT
DLBCL
JAK/
STAT
STAT3 Liquid,
Solid Tumors
STAT3 Autoimmune, Fibrotic Diseases

Pegasus Platform Internal Leveraging the capabilities of our Pegasus platform, we are advancing multiple degrader programs in immune-inflammatory and genetically defined oncology indications
Partnered Our strategic collaboration with Sanofi includes a second earlier stage undisclosed program
Our strategic collaboration with Vertex is focused on the research and development of degraders against at least 6 targets in disease areas outside of our core strategic focus of immunology-inflammation and oncology

Oncology Immunology-Inflammation *Kymera will have the option to participate in the development of Sanofi-partnered programs in the U.S. during clinical development
Program/
Indication(s)
Discovery Pre-
Clinical
Clinical Next
Milestone
Rights*

IRAK4

HS (Focus),
AD, RA,
Others
KT-474
Next
Generation
IRAKIMiD
(IRAK4, Ikaros, Aiolos)

MYD88
MT

DLBCL
STAT3

Liquid,
Solid
Tumors
STAT3

Autoimmune, Fibrotic
Diseases

Internal Leveraging the capabilities of our Pegasus platform, we are advancing multiple degrader programs in immune-inflammatory and genetically defined oncology indications
Partnered Our strategic collaboration with Sanofi includes a second earlier stage undisclosed program
Our strategic collaboration with Vertex is focused on the research and development of degraders against at least 6 targets in disease areas outside of our core strategic focus of immunology-inflammation and oncology

Oncology Immunology-Inflammation
*Kymera will have the option to participate in the development of Sanofi-partnered programs in the U.S. during clinical development

A First Target: IRAK4

Our lead candidate addresses IRAK4, a key component of a signaling pathway implicated in the pathophysiology of multiple diseases, including inflammatory and autoimmune diseases and cancers. One of the challenges in addressing IRAK4 is that you have to target both its scaffolding and kinase functions to effectively block signaling. Conventional kinase inhibitors affect only the kinase function. Targeted protein degradation is the only way to effectively address both functions with one drug.

Pre-clinical studies of Kymera’s novel small molecule degraders have demonstrated complete suppression of IRAK4, reversing inflammation in human cells and disease models superior to kinase inhibitors. Similarly in MYD88-driven B cell lymphomas, pre-clinical studies showed highly selective degradation of IRAK4 and tumor regression both alone and in combination with BTK inhibition.

Kymera CMO Jared Gollob explains IRAK4 | Length: 0:55